Carroll Financial Associates’s Bio-Rad Laboratories Class A BIO Stock Holding History

Carroll Financial Associates’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$5K	Sell	7 -3	-30%	-$2.25K	﹤0.01%	1323
2021 Q3	$7K	Buy	10 +3	+43%	+$2.25K	﹤0.01%	1305
2021 Q2	$4K	Hold	7	–	–	﹤0.01%	1467
2021 Q1	$3K	Hold	7	–	–	﹤0.01%	1436
2020 Q4	$4K	Hold	7	–	–	﹤0.01%	1279
2020 Q3	$3K	Sell	7 -13	-65%	-$6.58K	﹤0.01%	1259
2020 Q2	$9K	Buy	20 +13	+186%	+$5.74K	﹤0.01%	1048
2020 Q1	$2K	Hold	7	–	–	﹤0.01%	1279
2019 Q4	$2K	Hold	7	–	–	﹤0.01%	1362
2019 Q3	$2K	Hold	7	–	–	﹤0.01%	1325
2019 Q2	$2K	Buy	+7	New	+$2.1K	﹤0.01%	1358

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Carroll Financial Associates's BIO Position: Q4 2021 in Review

Carroll Financial Associates reduced its Bio-Rad Laboratories Class A (BIO) stake by 30% in Q4 2021, selling an estimated $2.25K and leaving 7 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1323.

Carroll Financial Associates first reported a position in BIO in Q2 2019 and has held it in 11 quarters since. The position peaked at $9K in Q2 2020. 534 funds tracked by Wall St. Rank hold BIO as of Q4 2021.

Carroll Financial Associates held 7 shares of Bio-Rad Laboratories Class A worth $5K as of Q4 2021.
Carroll Financial Associates sold 3 Bio-Rad Laboratories Class A shares in Q4 2021, an estimated $2.25K.
Bio-Rad Laboratories Class A made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1323 holding.
Carroll Financial Associates first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and has held it in 11 quarters since.
Carroll Financial Associates's Bio-Rad Laboratories Class A position peaked at $9K in Q2 2020.
534 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.